Newsletter sign up

I consent to having ADC Review collect all data required on this form

Check out our Privacy Policy for the full story on how we protect and manage your personal submitted data.

ADC University Our services

ADC Review
is made possible by:

Antibody–Drug Conjugates: Oncology and Beyond

Published on 23rd May

Antibody–Drug Conjugates (ADCs) combine the selectivity of antibodies with the efficacy of small molecule drugs, allowing for more precise therapeutic approaches. This symposium will explore the opportunities and challenges of ADCs for cancer, and the need to resolve these open questions in order to fulfill the larger promise of this technology. We will also consider use of ADCs beyond cancer into other disease indications including autoimmune disease, difficult-to-treat bacterial infections, and atherosclerosis.

Organizers  Speakers
Gene Dubowchik, Ph.D,
Bristol-Myers Squibb
Philip E. Brandish, Ph.D,
Merck & Co.
Lynn M. Abell, Ph.D,
Bristol-Myers Squibb
Ryan Fleming, Ph.D,
Pamela A. Trail, Ph.D,
Regeneron Pharmaceuticals Inc.
Rakesh K. Jain, Ph.D,
Harvard University
Sonya Dougal, Ph.D,
The New York Academy of Sciences
Christopher J. O’Donnell, Ph.D,
Caitlin McOmish, Ph.D,
The New York Academy of Sciences
Laura Saunders, Ph.D,
Greg Thurber, Ph.D
University of Michigan

Note: Poster Abstract Deadline is September 15, 2017

Photo: New York city skyline. Courtesy: © 2017 Fotolia. Used with permission.

Print Friendly, PDF & Email


Facebook share Twitter share Linkedin share Google Plus share

Featured Event

Topics to be Covered Introduction To Antibody Conjugates Overview Of Techniques In Quantitative Pharmacology No Such Thing As A Magic Bullet: The Hidden Challenges Of ADC Discovery And Development...

Skip to toolbar